Ondine’s Steriwave Phase III Trial Nears Completion with 93% Patient Enrolment

Ondine Biomedical Inc. has announced that its Phase III clinical trial for the Steriwave nasal photodisinfection system has reached 93% patient enrolment, marking a significant milestone toward study completion. The trial is evaluating Steriwave’s effectiveness in reducing surgical site infections, with final enrolment expected soon and results anticipated to support regulatory and commercial advancement.

Accelerating Progress in Infection Prevention Trials

The near-complete enrolment underscores strong clinical momentum for Steriwave, a light-activated antimicrobial therapy designed to rapidly eliminate pathogens in the nasal cavity. Surgical site infections remain a persistent global healthcare challenge, and innovations like Steriwave could offer a non-antibiotic approach to reducing infection risks, particularly amid rising antimicrobial resistance concerns.

Strategic Implications for Commercial Expansion

This milestone positions Ondine Biomedical Inc. to potentially accelerate regulatory submissions and expand its presence in hospital infection control markets. Positive trial outcomes could strengthen the company’s commercial strategy, enabling broader adoption across surgical settings and reinforcing its role in advancing photodisinfection technologies within the global healthcare landscape.